Navigation Links
Theravalues Confirms Beneficial Effects of Theracurmin™ on Diastolic Function in Hypertensive Patients
Date:11/10/2011

ORLANDO, Fla., Nov. 10, 2011 /PRNewswire/ -- Theravalues, a Japan based bio-venture, announced today that Theracurmin™, its curcumin-based product, impacts positively on the prevention of heart failure and its progression for the first time in history. During the human clinical trial started with the registration in July 2010, conducted by the company with National Hospital Organization Kyoto Medical Center and University of Shizuoka, Japan, the researchers found that Theracurmin™, which is absorbed by the body at a rate 27 times higher than curcumin powder, could effectively prevent diastolic failure.

(Logo:  http://photos.prnewswire.com/prnh/20111110/FL04434LOGO)

Dr. Tatsuya Morimoto, Professor at the Division of Molecular Medicine School of Pharmaceutical Sciences, at the University of Shizuoka said, "We are extremely excited to discover that Theracurmin™ has positive effects in curbing left ventricular diastolic failure at a statistically significant level." In the 24-week human trial, Theracurmin™, the absorption-enhanced curcumin invented by Theravalues, was prescribed for 30 subjects with left ventricular diastolic failure and their symptoms improved significantly. "The result of the study encourages patients and the elderly who have been suffering chronic cardiac problems," he added.

Curcumin, a polyphenol derived from turmeric (Curcuma Longa L,) has anti-inflammatory and anti-oxidant therapeutic properties. These properties effectively treat chronic inflammatory diseases. However, it has poor bioavailability due to its low oral absorption. Through Theracurmin™, Theravalues invented an innovative technology to solve this problem by creating surface controlled colloidal dispersion.

The FDA has approved Theracurmin™ for clinical trial in the United States. Last month, The University of Texas MD Anderson Cancer Center began treatment of malignant tumors caused by progressive cancer with Theracurmin™.

Mr. Hashimoto, the Representative Director and President of Theravalues said, "Theracurmin™ brings several exciting avenues of opportunity. We are confident about the potential power of Theracurmin™ not only for heart failure, but also for many incurable diseases and the maintenance of wellness of the people around the globe."

"While we were fascinated by the versatility of curcumin to help treat many diseases, its low oral absorption was the greatest challenge. Theracurmin™ improved the absorption of curcumin, making it 27 times higher than curcumin powder," said Dr. Koji Hasegawa, Director of the Division of Translational Research at National Hospital Organization Kyoto Medical Center. "In addition to its effectiveness on diastolic failure, we have been studying other application of Theracurmin™ to broaden its application into cancers, hepatic functions, skin conditions, ALS and Alzheimer's disease," he continued.

ABOUT THERAVALUES CORPORATION

Founded in 2007, Japan-based Theravalues Corporation strives to deliver better physical and mental health which gives much satisfaction to people around the world. Theravalues creates value through innovation, developing foods, medicines and technological models that achieve high satisfaction and healthy lives.

Learn more at www.theravalues.com/english  

Contact: Masami Hasegawa (Theravalues, Japan)
+81.3.3234.7677
mhasegawa@theravalues.com


'/>"/>
SOURCE Theravalues Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
2. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
3. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
4. Mylan Confirms Four First-to-File Challenges
5. GDFII/L&P Confirms Target Date Extension Of U.S. ITC Sucralose Ruling
6. NIH News Confirms Trend in Stem Cell Storage Facilities, says CEO of San Diego-based Bio-Matrix Scientific Group
7. Dow AgroSciences Confirms Efficacy of Zinc Finger Nucleases for Precise Genome Modification in Maize
8. Independent U.S. Study Confirms Veritides Ceeker(TM) Handheld Device Detects Anthrax With Outstanding Accuracy and Reliability
9. Independent Study Confirms Superior Properties of ZPC(TM) Enhanced Calcium Composite Bone Grafts
10. ImmuneRegen BioSciences Confirms Homsperas Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration
11. Analysis confirms that nano-related research has strong multidisciplinary roots
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- GlobeImmune, Inc. today announced it has entered into a ... of its common stock to NantCell, Inc., a member ... sale of its common stock, NantCell has agreed to ... 200,000 shares, an estimated $2.0 million in value, of ... to enter into this strategic agreement with NantCell," said ...
(Date:3/23/2017)... 23, 2017 Kineta, Inc., a biotechnology ... therapies in immuno-oncology, today announced the discovery and ... compounds that activate interferon response factor 3 (IRF3) ... immune-mediated tumor regression in a murine colon carcinoma ... demonstrated complete tumor regression to initial drug treatment ...
(Date:3/23/2017)... GREENWOOD VILLAGE, Colo. , March 23, 2017 /PRNewswire/ ... million in Series A financing and note conversion to ... products. Cool Planet is focused on developing products that ... raised nearly $30 million in the last 18 months. ... Coppel and North Bridge Venture Partners. ...
(Date:3/22/2017)... March 22, 2017 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), ... Center (RGC), U.K. Biobank and GSK to generate genetic sequence ... resource. The initiative will enable researchers to gain valuable insights ... a wide range of serious and life threatening diseases. ... Genetic evidence ...
Breaking Biology Technology:
(Date:2/28/2017)... News solutions for biometrics, bag drop and New ADA-compliant kiosk ... At PTE 2017 ... Materna will present its complete end-to-end passenger journey, from ... benefit for passengers. To accelerate the whole passenger handling process, ... to take passengers through the complete integrated process with a ...
(Date:2/24/2017)... , Feb. 24, 2017  EyeLock LLC, a leader of ... elite iris biometric solution on the latest Qualcomm® ... at Mobile World Congress 2017 (February 27 ... in Hall 3, Stand 3E10. ... Haven™ security platform—a combination of hardware, software ...
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a community ... that it has received Laboratory Accreditation from the ... is presented to laboratories that meet stringent requirements ... scientifically rigorous processes. "Genos is committed ... laboratory practices. We,re honored to be receiving CAP ...
Breaking Biology News(10 mins):